Claims for Patent: 5,453,446

Summary for Patent: 5,453,446

Title:	Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
Abstract:	R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
Inventor(s):	Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Berger-Paskin; Tirtsah (Raanana, IL), Yellin; Haim (Ramat-Gan, IL)
Assignee:	Teva Pharmaceutical Industries, Ltd. (Jerusalem, IL) Technion Research and Development Foundation Ltd. (Haifa, IL)
Application Number:	08/255,046
Patent Claims:	1. A method of treating a subject for Parkinson's disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the subject. 2. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered orally. 3. The method of claim 2, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 20 mg per daily dosage unit. 4. The method of claim 2, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 5 to 10 mg per daily dosage unit. 5. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered rectally. 6. The method of claim 5, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 20 mg per daily dosage unit. 7. The method of claim 5, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 5 to 10 mg per daily dosage unit. 8. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered transdermally. 9. The method of claim 8, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 20 mg per daily dosage unit. 10. The method of claim 8, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 5 to 10 mg per daily dosage unit. 11. The method of claim 1, wherein R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof is administered parenterally. 12. The method of claim 11, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 1 to 10 mg per mL per daily dosage unit. 13. The method of claim 12, wherein the amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof administered is 2 to 5 mg per mL per daily dosage unit. 14. The method of claim 13 which further comprises administering to the subject a decarboxylase inhibitor in an amount effective to ensure L-Dopa uptake. 15. The method of claim 14, wherein the decarboxylase inhibitor is Carbidopa. 16. The method of claim 15, wherein the decarboxylase inhibitor is benserazide. 17. The method of claim 1 which further comprises administering to the subject Levodopa in an amount relative to the amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat the disease. 18. The method of claim 1 which further comprises administering to the subject a decarboxylase inhibitor in an amount effective to ensure L-Dopa uptake. 19. The method of claim 18, wherein the decarboxylase inhibitor is Carbidopa. 20. The method of claim 18, wherein the decarboxylase inhibitor is benserazide.